{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:51:17Z","timestamp":1791456677326,"version":"4.3.4"},"reference-count":99,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hypertension remains a major contributor to global cardiovascular morbidity despite decades of available therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This review advances an endocrinological framework in which chronic hypertension, including resistant hypertension, is understood as a consequence of dysregulated hormonal control of renal sodium handling, mediated by excess renin-angiotensin II activity, inappropriate aldosterone excess, or both.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Within this framework, the traditional binary distinction between \u201cessential\u201d and \u201csecondary\u201d hypertension gives way to a mechanistic continuum characterized by biochemical phenotyping using renin and aldosterone. Primary aldosteronism (PA) is now recognized as existing across a spectrum of severity that is broader than classical diagnostic thresholds suggest, and aldosterone dysregulation, even at subclinical levels, confers adverse cardiorenal outcomes exceeding those of renin-dependent hypertension. Mineralocorticoid receptor antagonists (MRAs) are effective when aldosterone excess is the dominant mechanism but do not correct the underlying endocrinopathy and may be limited by tolerability at the doses required to achieve full biochemical targets. Highly selective second-generation aldosterone synthase inhibitors (ASIs), including baxdrostat and lorundrostat, directly suppress aldosterone production, mirror the biochemical response seen after surgical adrenalectomy, and may confer disease-modifying effects beyond blood pressure reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Integrated into a mechanism-first clinical algorithm driven by renin and aldosterone profiling, ASIs and MRAs offer the potential to transform management of low-renin and PA-spectrum hypertension, moving clinicians from empirical, add-on drug strategies toward individualized, pathophysiology-guided care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajh\/hpag078","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:57:30Z","timestamp":1783511850000},"page":"S66-S77","source":"Crossref","is-referenced-by-count":0,"title":["From low renin to the primary aldosteronism spectrum: aldosterone synthase inhibitors and the endocrine management of hypertension"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8129-9360","authenticated-orcid":false,"given":"Gregory A","family":"Kline","sequence":"first","affiliation":[{"name":"Cumming School of Medicine, University of Calgary , Calgary, AB,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"2026100806025594300_hpag078-B1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jash.2014.03.003","article-title":"Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality","volume":"8","author":"Irvin","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"2026100806025594300_hpag078-B2","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","article-title":"Incidence and prognosis of resistant hypertension in hypertensive patients","volume":"125","author":"Daugherty","year":"2012","journal-title":"Circulation"},{"key":"2026100806025594300_hpag078-B3","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/S0140-6736(16)31679-8","article-title":"Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990\u20132015: a systematic analysis for the global burden of disease study 2015","volume":"388","author":"GBD 2015 Risk Factors Collaborators","year":"2016","journal-title":"Lancet (London, England)"},{"key":"2026100806025594300_hpag078-B4","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1177\/2047487320937492","article-title":"Antihypertensive strategies and hypertension control in Sub-Saharan africa","volume":"28","author":"Cavagna","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2026100806025594300_hpag078-B5","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1161\/CIRCRESAHA.120.318729","article-title":"Hypertension in low- and Middle-Income countries","volume":"128","author":"Schutte","year":"2021","journal-title":"Circ Res"},{"key":"2026100806025594300_hpag078-B6","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jama.2020.14545","article-title":"Trends in blood pressure control among US adults with hypertension, 1999-2000 to 2017-2018","volume":"324","author":"Muntner","year":"2020","journal-title":"JAMA - J Am Med Assoc"},{"key":"2026100806025594300_hpag078-B7","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1001\/jama.2023.7022","article-title":"Excess mortality and years of potential life lost among the black population in the US, 1999-2020","volume":"329","author":"Caraballo","year":"2023","journal-title":"JAMA"},{"key":"2026100806025594300_hpag078-B8","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1161\/HYPERTENSIONAHA.121.17570","article-title":"Racial\/ethnic disparities in hypertension prevalence, awareness, treatment, and control in the United States, 2013 to 2018","volume":"78","author":"Aggarwal","year":"2021","journal-title":"Hypertension"},{"key":"2026100806025594300_hpag078-B9","doi-asserted-by":"crossref","first-page":"E2249930","DOI":"10.1001\/jamanetworkopen.2022.49930","article-title":"Blood pressure control among black and white adults following a quality improvement program in a large integrated health system","volume":"6","author":"Harrison","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026100806025594300_hpag078-B10","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.mayocp.2022.12.024","article-title":"Disruption in blood pressure control with the COVID-19 pandemic: the PCORnet blood pressure control laboratory","volume":"98","author":"Chamberlain","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"2026100806025594300_hpag078-B11","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/jama.2023.3322","article-title":"Heterogeneity in blood pressure response to 4 antihypertensive drugs: a randomized clinical trial","volume":"329","author":"Sundstr\u00f6m","year":"2023","journal-title":"JAMA"},{"key":"2026100806025594300_hpag078-B12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/0002-9343(75)90527-6","article-title":"The renin axis and vasoconstriction volume analysis for understanding and treating renovascular and renal hypertension","volume":"58","author":"Laragh","year":"1975","journal-title":"Am J Med"},{"key":"2026100806025594300_hpag078-B13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0895-7061(03)00867-7","article-title":"Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHAT","volume":"16","author":"Laragh","year":"2003","journal-title":"Am J Hypertens"},{"key":"2026100806025594300_hpag078-B14","first-page":"2897","article-title":"Regulation of arterial pressure: role of pressure natriuresis and diuresis","volume":"45","author":"Hall","year":"1986","journal-title":"Fed Proc"},{"key":"2026100806025594300_hpag078-B15","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/01.HYP.15.6.547","article-title":"Abnormal pressure natriuresis a cause or a consequence of hypertension?","volume":"15","author":"Hall","year":"1990","journal-title":"Hypertension"},{"key":"2026100806025594300_hpag078-B16","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/ajh\/hpw073","article-title":"Logical issues with the pressure natriuresis theory of chronic hypertension","volume":"29","author":"Kurtz","year":"2016","journal-title":"Am J Hypertens"},{"key":"2026100806025594300_hpag078-B17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00000441-196901000-00002","article-title":"Re-examination of the hemodynamics of hypertension","volume":"257","author":"Frohlich","year":"1969","journal-title":"Am J Med Sci"},{"key":"2026100806025594300_hpag078-B18","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1210\/jc.2018-02697","article-title":"Functional hypogonadotropic hypogonadism in men: underlying neuroendocrine mechanisms and natural history","volume":"104","author":"Dwyer","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100806025594300_hpag078-B19","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1210\/jc.2014-3802","article-title":"Sequential versus continual purified urinary FSH\/hCG in men with idiopathic hypogonadotropic hypogonadism","volume":"100","author":"Zhang","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100806025594300_hpag078-B20","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1097\/00004872-200205000-00033","article-title":"Renal vein renin measurements accurately identify renovascular hypertension caused by total occlusion of the renal artery","volume":"20","author":"Rossi","year":"2002","journal-title":"J Hypertens"},{"key":"2026100806025594300_hpag078-B21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1161\/01.HYP.0000171185.25749.5b","article-title":"Renin-dependent hypertension caused by nonfocal stenotic aberrant renal arteries: proof of a new syndrome","volume":"46","author":"Kem","year":"2005","journal-title":"Hypertension"},{"key":"2026100806025594300_hpag078-B22","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12902-020-00620-6","article-title":"Patients with pheochromocytoma exhibit low aldosterone renin ratio-preliminary reports","volume":"20","author":"Yamada","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"2026100806025594300_hpag078-B23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0046-8177(86)80469-5","article-title":"Hyperplasia of renin-containing cells in a malignant pheochromocytoma: an immunohistochemical and semiquantitative study","volume":"17","author":"Kimura","year":"1986","journal-title":"Hum Pathol"},{"key":"2026100806025594300_hpag078-B24","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/14779072.2018.1540301","article-title":"Pathophysiology of essential hypertension: an update","volume":"16","author":"Saxena","year":"2018","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2026100806025594300_hpag078-B25","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1161\/CIRCRESAHA.121.318064?download=true","article-title":"Renin cells, the kidney, and hypertension","volume":"128","author":"Sequeira-Lopez","year":"2021","journal-title":"Circ Res"},{"key":"2026100806025594300_hpag078-B26","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1093\/ndt\/gfh865","article-title":"Long-term follow-up of atherosclerotic renovascular disease. Beneficial effect of ACE inhibition","volume":"20","author":"Losito","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"2026100806025594300_hpag078-B27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0140-6736(84)91099-7","article-title":"Effect of captopril on hypertension due to phaeochromocytoma","volume":"324","author":"Loute","year":"1984","journal-title":"Lancet"},{"key":"2026100806025594300_hpag078-B28","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0140-6736(85)90330-7","article-title":"Captopril and phaeochromocytoma","volume":"326","author":"Israeli","year":"1985","journal-title":"Lancet"},{"key":"2026100806025594300_hpag078-B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjhyper.2003.08.015","article-title":"Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients","volume":"17","author":"Alderman","year":"2004","journal-title":"Am J Hypertens"},{"key":"2026100806025594300_hpag078-B30","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ajh.2010.98","article-title":"Plasma renin activity predicts blood pressure responses to \u03b2-blocker and thiazide diuretic as monotherapy and Add-On therapy for hypertension","volume":"23","author":"Turner","year":"2010","journal-title":"Am J Hypertens"},{"key":"2026100806025594300_hpag078-B31","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/ajh.2008.275","article-title":"Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises","volume":"22","author":"Sealey","year":"2009","journal-title":"Am J Hypertens"},{"key":"2026100806025594300_hpag078-B32","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"key":"2026100806025594300_hpag078-B33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1530\/EJE-13-0477","article-title":"Cushing\u2019s disease and hypertension: in vivo and in vitro study of the role of the renin-angiotensin-aldosterone system and effects of medical therapy","volume":"170","author":"van der Pas","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"2026100806025594300_hpag078-B34","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41371-017-0002-5","article-title":"Congenital adrenal hyperplasia causing hypertension: an illustrative review","volume":"32","author":"Hinz","year":"2018","journal-title":"J Hum Hypertens"},{"key":"2026100806025594300_hpag078-B35","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00760-17","article-title":"In vivo 11\u03b2-Hydroxysteroid dehydrogenase inhibition in Posaconazole-Induced hypertension and hypokalemia","volume":"61","author":"Thompson","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026100806025594300_hpag078-B36","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1056\/NEJM199110243251706","article-title":"Licorice-Induced hypermineralocorticoidism","volume":"325","author":"Farese","year":"1991","journal-title":"N Engl J Med"},{"key":"2026100806025594300_hpag078-B37","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and safety of osilodrostat in patients with cushing\u2019s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026100806025594300_hpag078-B38","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1210\/jc.2008-0040","article-title":"Generalized glucocorticoid resistance: clinical aspects, molecular mechanisms, and implications of a rare genetic disorder","volume":"93","author":"Charmandari","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100806025594300_hpag078-B39","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.tem.2005.02.011","article-title":"Monogenic low renin hypertension","volume":"16","author":"New","year":"2005","journal-title":"Trends Endocrinol Metab"},{"key":"2026100806025594300_hpag078-B40","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1097\/00004872-200411000-00026","article-title":"Low-renin status in therapy-resistant hypertension: a clue to efficient treatment","volume":"22","author":"Eide","year":"2004","journal-title":"J Hypertens"},{"key":"2026100806025594300_hpag078-B41","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0002-9610(64)90252-1","article-title":"Clinical characteristics of primary aldosteronism from an analysis of 145 cases","volume":"107","author":"Conn","year":"1964","journal-title":"Am J Surg"},{"key":"2026100806025594300_hpag078-B42","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/0002-9343(61)90080-8","article-title":"Studies on the expanded extracellular fluid and the responses to various stimuli in primary aldosteronism","volume":"30","author":"Biglieri","year":"1961","journal-title":"Am J Med"},{"key":"2026100806025594300_hpag078-B43","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1172\/JCI106087","article-title":"Stimulation and suppression of aldosterone in plasma of normal man and in primary aldosteronism","volume":"48","author":"Horton","year":"1969","journal-title":"J Clin Invest"},{"key":"2026100806025594300_hpag078-B44","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.1365-2265.1975.tb01559.x","article-title":"Response of plasma aldosterone to fludrocortisone in primary hyperaldosteronism and other forms of hypertension","volume":"4","author":"Padfield","year":"1975","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026100806025594300_hpag078-B45","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1210\/jcem-57-5-892","article-title":"Single dose captopril as a diagnostic test for primary aldosteronism","volume":"57","author":"Lyons","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100806025594300_hpag078-B46","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/archinte.1981.00340130033011","article-title":"A screening test to identify Aldosterone-Producing adenoma by measuring plasma renin activity: results in hypertensive patients","volume":"141","author":"Hiramatsu","year":"1981","journal-title":"Arch Intern Med"},{"key":"2026100806025594300_hpag078-B47","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1440-1681.1993.tb01687.x","article-title":"Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers","volume":"20","author":"Gordon","year":"1993","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2026100806025594300_hpag078-B48","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/sj.jhh.1001013","article-title":"High prevalence of primary aldosteronism in the tayside hypertension clinic population","volume":"14","author":"Lim","year":"2000","journal-title":"J Hum Hypertens"},{"key":"2026100806025594300_hpag078-B49","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S0025-6196(11)62105-8","article-title":"TS. Validity of the Aldosterone-Renin ratio used to screen for primary aldosteronism","volume":"76","author":"Montori","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"2026100806025594300_hpag078-B50","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/01.HYP.37.6.1440","article-title":"Captopril suppression versus salt loading in confirming primary aldosteronism","volume":"37","author":"Agharazii","year":"2001","journal-title":"Hypertension"},{"key":"2026100806025594300_hpag078-B51","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1097\/00004872-200311000-00025","article-title":"High rate of detection of primary aldosteronism, including surgically treatable forms, after \u201cnon-selective\u201d screening of hypertensive patients","volume":"21","author":"Stowasser","year":"2003","journal-title":"J Hypertens"},{"key":"2026100806025594300_hpag078-B52","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1210\/jc.2008-0104","article-title":"Case detection, diagnosis, and treatment of patients with primar y aldosteronism: an endocrine society clinical practice guideline","volume":"93","author":"Funder","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100806025594300_hpag078-B53","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100806025594300_hpag078-B54","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/HYPERTENSIONAHA.124.24153","article-title":"Characterizing the origins of primary aldosteronism","volume":"82","author":"Brown","year":"2025","journal-title":"Hypertension"},{"key":"2026100806025594300_hpag078-B55","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1210\/clinem\/dgae145","article-title":"The spectrum of dysregulated aldosterone production: an international human physiology study","volume":"109","author":"Parksook","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100806025594300_hpag078-B56","doi-asserted-by":"crossref","first-page":"948","DOI":"10.7326\/ANNALS-24-03153","article-title":"Confirmatory testing for primary aldosteronism: a study of diagnostic test accuracy","volume":"178","author":"Leung","year":"2025","journal-title":"Ann Intern Med"},{"key":"2026100806025594300_hpag078-B57","doi-asserted-by":"crossref","first-page":"e26435","DOI":"10.1161\/HYPERTENSIONAHA.125.26435","article-title":"Big data approach to assessment of an aldosterone-renin ratio for detection of potential surgical cases of primary aldosteronism","volume":"83","author":"Leung","year":"2026","journal-title":"Hypertension"},{"key":"2026100806025594300_hpag078-B58","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/ejendo\/lvaf170","article-title":"Discordance and shortcomings of aldosterone suppression tests in primary aldosteronism","volume":"193","author":"Tsai","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"2026100806025594300_hpag078-B59","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1161\/HYPERTENSIONAHA.123.21983","article-title":"Long-Term Follow-Up of patients with elevated aldosterone-to-renin ratio but negative confirmatory test: the progression of primary aldosteronism phenotypes","volume":"81","author":"Buffolo","year":"2024","journal-title":"Hypertension"},{"key":"2026100806025594300_hpag078-B60","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11886-022-01826-x","article-title":"Racial and ethnic disparities in hypertension: barriers and opportunities to improve blood pressure control","volume":"25","author":"Abrahamowicz","year":"2023","journal-title":"Curr Cardiol Rep"},{"key":"2026100806025594300_hpag078-B61","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.125.048888","article-title":"Bilateral adrenal primary aldosteronism is uniformly present in hypertensive Afro-Caribbean First-Generation immigrants to Western Canada","author":"Leung","year":"2026","journal-title":"J Am Heart Assoc"},{"key":"2026100806025594300_hpag078-B62","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1210\/er.2018-00139","article-title":"The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment","volume":"39","author":"Vaidya","year":"2018","journal-title":"Endocr Rev"},{"key":"2026100806025594300_hpag078-B63","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.123.066389","article-title":"Subclinical primary aldosteronism and cardiovascular health: a population-based cohort study","volume":"149","author":"Hundemer","year":"2024","journal-title":"Circulation"},{"key":"2026100806025594300_hpag078-B64","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026100806025594300_hpag078-B65","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"2026100806025594300_hpag078-B66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2024.05.033","article-title":"2024 European society of hypertension clinical practice guidelines for the management of arterial hypertension","volume":"126","author":"Kreutz","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2026100806025594300_hpag078-B67","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","article-title":"Primary aldosteronism: an endocrine society clinical practice guideline","volume":"110","author":"Adler","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100806025594300_hpag078-B68","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1210\/endrev\/bnad024","article-title":"Biomarkers to guide medical therapy in primary aldosteronism","volume":"45","author":"Hundemer","year":"2024","journal-title":"Endocr Rev"},{"key":"2026100806025594300_hpag078-B69","article-title":"2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","author":"Writing Committee Members","year":"2025","journal-title":"JACC"},{"key":"2026100806025594300_hpag078-B70","first-page":"e1280-9","article-title":"Time to benefit of surgery vs. Targeted medical therapy for patients with primary aldosteronism: a meta-analysis","author":"Samnani","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100806025594300_hpag078-B71","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf595","article-title":"Persistent renin suppression after unilateral adrenalectomy for primary aldosteronism: implications for adverse outcome?","author":"St\u00fcfchen","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100806025594300_hpag078-B72","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1161\/HYPERTENSIONAHA.123.22281?download=true","article-title":"Unilateral primary aldosteronism: long-term disease recurrence after adrenalectomy","volume":"81","author":"Tetti","year":"2024","journal-title":"Hypertension"},{"key":"2026100806025594300_hpag078-B73","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low-dose spironolactone in subjects with resistant hypertension","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am J Hypertens"},{"key":"2026100806025594300_hpag078-B74","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/cen.14351","article-title":"Outcomes in unilateral primary aldosteronism after surgical or medical therapy","volume":"94","author":"Puar","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026100806025594300_hpag078-B75","doi-asserted-by":"publisher","first-page":"R147","DOI":"10.1530\/EJE-19-0215","article-title":"Therapy of endocrine disease: medical treatment of primary aldosteronism","volume":"181","author":"Lechner","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"2026100806025594300_hpag078-B76","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2213-8587(24)00308-5","article-title":"Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort","volume":"13","author":"Yang","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026100806025594300_hpag078-B77","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1001\/jamacardio.2018.2003","article-title":"Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism","volume":"3","author":"Hundemer","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026100806025594300_hpag078-B78","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4081\/aiua.2021.4.489","article-title":"Drug-induced gynecomastia: a systematic review and meta-analysis of randomized clinical trials","volume":"93","author":"Trinchieri","year":"2021","journal-title":"Arch Ital DI Urol Androl"},{"key":"2026100806025594300_hpag078-B79","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/ehjcvp\/pvad045","article-title":"Initiation of eplerenone or spironolactone, treatment adherence, and associated outcomes in patients with new-onset heart failure with reduced ejection fraction: a nationwide cohort study","volume":"9","author":"Larsson","year":"2023","journal-title":"Eur Hear J - Cardiovasc Pharmacother"},{"key":"2026100806025594300_hpag078-B80","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1530\/EJE-12-0631","article-title":"Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism","volume":"168","author":"Fourkiotis","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"2026100806025594300_hpag078-B81","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/ndt\/gfae004","article-title":"When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases","volume":"39","author":"Kobayashi","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026100806025594300_hpag078-B82","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1161\/CIRCULATIONAHA.118.033597?download=true","article-title":"Primary aldosteronism: practical approach to diagnosis and management","volume":"138","author":"Brian Byrd","year":"2018","journal-title":"Circulation"},{"key":"2026100806025594300_hpag078-B83","doi-asserted-by":"crossref","first-page":"102638","DOI":"10.1016\/j.dsx.2022.102638","article-title":"Finerenone in diabetic kidney disease: a systematic review and critical appraisal","volume":"16","author":"Singh","year":"2022","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"2026100806025594300_hpag078-B84","article-title":"Amiloride: a review","volume":"21","author":"Sun","year":"2020","journal-title":"JRAAS - J Renin-Angiotensin-Aldosterone Syst"},{"key":"2026100806025594300_hpag078-B85","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/clc.20324","article-title":"A comparison of the aldosterone-blocking agents eplerenone and spironolactone","volume":"31","author":"Struthers","year":"2008","journal-title":"Clin Cardiol"},{"key":"2026100806025594300_hpag078-B86","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1001\/jama.2025.5129","article-title":"Spironolactone vs amiloride for resistant hypertension: a randomized clinical trial","volume":"333","author":"Lee","year":"2025","journal-title":"JAMA"},{"key":"2026100806025594300_hpag078-B87","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","article-title":"Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026100806025594300_hpag078-B88","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/jch.13566","article-title":"Mineralocorticoid antagonists and ENaC inhibitors in hyperaldosteronism","volume":"21","author":"Hill","year":"2019","journal-title":"J of Clinical Hypertension"},{"key":"2026100806025594300_hpag078-B89","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"2026100806025594300_hpag078-B90","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","article-title":"Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension","volume":"393","author":"Flack","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100806025594300_hpag078-B91","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","article-title":"Lorundrostat efficacy and safety in patients with uncontrolled hypertension","volume":"392","author":"Laffin","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100806025594300_hpag078-B92","doi-asserted-by":"publisher","first-page":"e557","DOI":"10.1210\/clinem\/dgae823","article-title":"Aldosterone synthase inhibitors: a revival for treatment of renal and cardiovascular diseases","volume":"110","author":"Azizi","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100806025594300_hpag078-B93","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1056\/NEJMc2508629","article-title":"Phase 2a study of baxdrostat in primary aldosteronism","volume":"393","author":"Turcu","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100806025594300_hpag078-B94","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/HJH.0000000000004218","article-title":"Prolonged aldosterone suppression and renin upregulation after baxdrostat","volume":"44","author":"Rutten","year":"2026","journal-title":"J Hypertens"},{"key":"2026100806025594300_hpag078-B95","doi-asserted-by":"crossref","first-page":"408","DOI":"10.5694\/mja2.51438","article-title":"Detecting primary aldosteronism in Australian primary care: a prospective study","volume":"216","author":"Libianto","year":"2022","journal-title":"Med J Aust"},{"key":"2026100806025594300_hpag078-B96","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1161\/HYPERTENSIONAHA.125.24648","article-title":"Nationwide, pragmatic, direct-to-patient primary aldosteronism testing program","volume":"82","author":"Brown","year":"2025","journal-title":"Hypertension"},{"issue":"1","key":"2026100806025594300_hpag078-B97","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11102-024-01471-3","article-title":"Osilodrostat improves blood pressure and glycemic control in patients with Cushing\u2019s disease: a pooled analysis of LINC 3 and LINC 4 studies","volume":"28","author":"Fleseriu","year":"2025","journal-title":"Pituitary"},{"issue":"6","key":"2026100806025594300_hpag078-B98","doi-asserted-by":"crossref","first-page":"e70391","DOI":"10.1002\/clc.70391","article-title":"Efficacy and Safety of Baxdrostat for Hypertension: A Systematic Review and Meta-Analysis of Three Phase 2\/3 Randomized Controlled Trials","volume":"49","author":"Falodia","year":"2026","journal-title":"Clinical Cardiology"},{"issue":"7","key":"2026100806025594300_hpag078-B99","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/ajh\/hpaf246","article-title":"Lorundrostat for patients with uncontrolled hypertension: a systematic review with meta-analysis and trial sequential analysis","volume":"39","author":"Ribeiro","year":"2026","journal-title":"American Journal of Hypertension"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/39\/Supplement_1\/S66\/71667115\/hpag078.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/39\/Supplement_1\/S66\/71667115\/hpag078.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:03:13Z","timestamp":1791453793000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/39\/Supplement_1\/S66\/8875942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":99,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2026,10,8]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpag078","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,10,1]]}}}